Study of HRS-8080 and Dalpiciclib for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 75
- Breast cancer that has spread or come back in a distant part of the body
- You have had at least one round of hormone therapy that stopped working, OR you are starting your first treatment for advanced disease
- At least one tumor that can be measured on scans outside the brain
- Willing to use effective birth control during and for 7 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs (dalpiciclib and an HDAC inhibitor) for people with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 inhibitor treatment. The goal is to see if this new combination can help control the cancer.
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
This Phase 2 trial tests dalpiciclib (a cancer medicine) added to standard hormone therapy for women with advanced, hormone-receptor–positive and HER2-negative breast cancer that has serious “visceral crisis” symptoms (like fluid buildup, liver issues, or other urgent organ involvement). It aims to see whether this combination can shrink cancer and improve safety compared with hormone therapy alone.
This early-phase study tests HRS-1358 tablets in people with breast cancer that is locally advanced or has spread. It may help learn whether the drug can control cancer, while also checking safety and how the body handles it.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Hear when a new Unresectable or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.